Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Portik-Dobos, V.
Right arrow Articles by Ergul, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Portik-Dobos, V.
Right arrow Articles by Ergul, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:3063-3068, 2002
© 2002 by the American Diabetes Association, Inc.

Evidence for a Matrix Metalloproteinase Induction/Activation System in Arterial Vasculature and Decreased Synthesis and Activity in Diabetes

Vera Portik-Dobos1, Mark P. Anstadt2,3, Jimmie Hutchinson1, Mary Bannan2, and Adviye Ergul1,2,3

1 University of Georgia College of Pharmacy, Medical College of Georgia, Augusta, Georgia
2 Department of Surgery, Medical College of Georgia, Augusta, Georgia
3 Vascular Biology Center, Medical College of Georgia, Augusta, Georgia

Pathological remodeling characterized by extracellular matrix (ECM) deposition contributes to the diabetic vascular complications. Matrix metalloproteinases (MMPs) regulate ECM turnover. However, the expression profile of the MMP system in diabetic human tissue remains unknown. The objectives of this study were 1) to identify a local MMP induction/activation system that exists in arterial vasculature and 2) to determine how the MMP system may be altered in diabetes. Internal mammary artery specimens were obtained from patients who did (n = 14) and did not (n = 14) have diabetes and were undergoing coronary artery bypass grafting surgery. ECM inducer protein (EMMPRIN); membrane-type MMP (MT-MMP); and MMP-1, -2, and -9 were quantified by immunoblotting and densitometric scanning (pixels). Pro-MMP-1 and MMP-2 levels were decreased from 952 ± 120 and 1,081 ± 508 pixels, respectively, in nondiabetic tissue to 398 ± 62 and 249 ± 42 pixels in the diabetic tissue (P < 0.05). Both EMMPRIN and MT-MMP expression and total MMP activity were decreased by twofold in diabetic patients (P < 0.05). These results demonstrated for the first time that an MMP induction and activation system exists in human arterial vasculature and that it is downregulated in diabetes. Decreased MMP activity may contribute to increased collagen deposition and pathological remodeling in diabetes.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Arch SurgHome page
N. R. Sodha, M. Boodhwani, R. T. Clements, S.-H. Xu, K. R. Khabbaz, and F. W. Sellke
Increased Antiangiogenic Protein Expression in the Skeletal Muscle of Diabetic Swine and Patients
Arch Surg, May 1, 2008; 143(5): 463 - 470.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
U. Hiden, E. Glitzner, M. Ivanisevic, J. Djelmis, C. Wadsack, U. Lang, and G. Desoye
MT1-MMP Expression in First-Trimester Placental Tissue Is Upregulated in Type 1 Diabetes as a Result of Elevated Insulin and Tumor Necrosis Factor-{alpha} Levels
Diabetes, January 1, 2008; 57(1): 150 - 157.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
G. R. Willsky, L.-H. Chi, Y. Liang, D. P. Gaile, Z. Hu, and D. C. Crans
Diabetes-altered gene expression in rat skeletal muscle corrected by oral administration of vanadyl sulfate
Physiol Genomics, September 14, 2006; 26(3): 192 - 201.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
A. W.Y. Chung, Y. N. Hsiang, L. A. Matzke, B. M. McManus, C. van Breemen, and E. B. Okon
Reduced Expression of Vascular Endothelial Growth Factor Paralleled With the Increased Angiostatin Expression Resulting From the Upregulated Activities of Matrix Metalloproteinase-2 and -9 in Human Type 2 Diabetic Arterial Vasculature
Circ. Res., July 21, 2006; 99(2): 140 - 148.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
V. Portik-Dobos, A. K. Harris, W. Song, J. Hutchinson, M. H. Johnson, J. D. Imig, D. M. Pollock, and A. Ergul
Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R435 - R441.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
N. P. Kadoglou, S. S. Daskalopoulou, D. Perrea, and C. D. Liapis
Matrix Metalloproteinases and Diabetic Vascular Complications
Angiology, March 1, 2005; 56(2): 173 - 189.
[Abstract] [PDF]

Home page
 Vasc MedHome page
S. S. Signorelli, G. Malaponte, M. Libra, L. D. Pino, G. Celotta, V. Bevelacqua, M. Petrina, G. S Nicotra, M. Indelicato, P. M Navolanic, et al.
Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease
Vascular Medicine, February 1, 2005; 10(1): 1 - 6.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
M. H. Tayebjee, H. S. Lim, R. J. MacFadyen, and G. Y.H. Lip
Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 and -2 in Type 2 Diabetes: Effect of 1 year's cardiovascular risk reduction therapy
Diabetes Care, August 1, 2004; 27(8): 2049 - 2051.
[Full Text] [PDF]

Home page
 CirculationHome page
A. R. Brady, S. G. Thompson, F. G. R. Fowkes, R. M. Greenhalgh, J. T. Powell, and on behalf of the UK Small Aneurysm Trial Participa
Abdominal Aortic Aneurysm Expansion: Risk Factors and Time Intervals for Surveillance
Circulation, July 6, 2004; 110(1): 16 - 21.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. P. Anstadt, D. L. Franga, V. Portik-Dobos, A. Pennathur, M. Bannan, K. Mawulawde, and A. Ergul
Native Matrix Metalloproteinase Characteristics May Influence Early Stenosis of Venous Versus Arterial Coronary Artery Bypass Grafting Conduits
Chest, May 1, 2004; 125(5): 1853 - 1858.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Jesmin, I. Sakuma, Y. Hattori, and A. Kitabatake
Role of Angiotensin II in Altered Expression of Molecules Responsible for Coronary Matrix Remodeling in Insulin-Resistant Diabetic Rats
Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 2021 - 2026.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. Ergul, V. Portik-Dobos, A. D. Giulumian, M. M. Molero, and L. C. Fuchs
Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation
Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2225 - H2232.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. C. Frisbee
Remodeling of the skeletal muscle microcirculation increases resistance to perfusion in obese Zucker rats
Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H104 - H111.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
N. Marx, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, H. Scharnagl, V. Hombach, and W. Koenig
Antidiabetic PPAR{gamma}-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease
Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 283 - 288.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.